Publication Results

Generate Report

Add publications by marking their checkboxes, or

Early and late effects of aspirin and naproxen on microRNAs in the lung and blood of mice, either unexposed or exposed to cigarette smoke.

Izzotti A,  Balansky R,  Ganchev G,  Iltcheva M,  Longobardi M,  Pulliero A,  Camoirano A,  D'Agostini F,  Geretto M,  Micale RT,  La Maestra S,  Miller MS,  Steele VE,  De Flora S
Oncotarget 2017 Oct 17;8(49):85716-85748
PubMed ID: 29156752
PMC ID: PMC5689642
Groups or Programs: Chemopreventive Agent Development

Effect of weekly or daily dosing regimen of Gefitinib in mouse models of lung cancer.

Zhang Q,  Li R,  Chen X,  Lee SB,  Pan J,  Xiong D,  Hu J,  Miller MS,  Szabo E,  Lubet RA,  Wang Y,  You M
Oncotarget 2017 Sep 22;8(42):72447-72456
PubMed ID: 29069801
PMC ID: PMC5641144
Groups or Programs: Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer

Pioglitazone-mediated reversal of elevated glucose metabolism in the airway epithelium of mouse lung adenocarcinomas.

Xiong D,  Pan J,  Zhang Q,  Szabo E,  Miller MS,  Lubet RA,  Wang Y,  You M
JCI Insight 2017 Jul 6;2(13)
PubMed ID: 28679956
PMC ID: PMC5499364
Groups or Programs: Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer

Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents.

Xiong D,  Pan J,  Zhang Q,  Szabo E,  Miller MS,  Lubet RA,  You M,  Wang Y
Oncotarget 2017 Mar 21;8(12):18885-18900
PubMed ID: 27935865
PMC ID: PMC5386655
Groups or Programs: Chemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer

Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.

Seabloom DE,  Galbraith AR,  Haynes AM,  Antonides JD,  Wuertz BR,  Miller WA,  Miller KA,  Steele VE,  Miller MS,  Clapper ML,  O'Sullivan MG,  Ondrey FG
Cancer Prev Res (Phila) 2017 Feb;10(2):116-123
PubMed ID: 28052934
PMC ID: PMC5690483
Groups or Programs: Chemopreventive Agent Development

Blood and lung microRNAs as biomarkers of pulmonary tumorigenesis in cigarette smoke-exposed mice.

Izzotti A,  Balansky R,  Ganchev G,  Iltcheva M,  Longobardi M,  Pulliero A,  Geretto M,  Micale RT,  La Maestra S,  Miller MS,  Steele VE,  De Flora S
Oncotarget 2016 Dec 20;7(51):84758-84774
PubMed ID: 27713172
PMC ID: PMC5341294
Groups or Programs: Chemopreventive Agent Development

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.

Ebben JD,  Lubet RA,  Gad E,  Disis ML,  You M
Mol Carcinog 2016 Nov;55(11):1517-1525
PubMed ID: 26346412
PMC ID: PMC6019616
Groups or Programs: Chemopreventive Agent Development

Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report.

Miller MS,  Allen P,  Brentnall TA,  Goggins M,  Hruban RH,  Petersen GM,  Rao CV,  Whitcomb DC,  Brand RE,  Chari ST,  Klein AP,  Lubman DM,  Rhim AD,  Simeone DM,  Wolpin BM,  Umar A,  Srivastava S,  Steele VE,  Rinaudo JA
Pancreas 2016 Sep;45(8):1080-91
PubMed ID: 27518363
PMC ID: PMC4988336
Groups or Programs: Chemopreventive Agent DevelopmentCancer BiomarkersGastrointestinal and Other Cancers

Selective inhibition by aspirin and naproxen of mainstream cigarette smoke-induced genotoxicity and lung tumors in female mice.

Balansky R,  Ganchev G,  Iltcheva M,  Micale RT,  La Maestra S,  D'Oria C,  Steele VE,  De Flora S
Arch Toxicol 2016 May;90(5):1251-60
PubMed ID: 26104855
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

Land SR,  Walcott FL,  Liu Q,  Wickerham DL,  Costantino JP,  Ganz PA
J Natl Cancer Inst 2016 Apr;108(4)
PubMed ID: 26615179
PMC ID: PMC4675829
Groups or Programs: Chemopreventive Agent Development
Clinical Trials: Breast Cancer Prevention Trial (BCPT)

Global Mortality Impact of the 1957-1959 Influenza Pandemic.

Viboud C,  Simonsen L,  Fuentes R,  Flores J,  Miller MA,  Chowell G
J Infect Dis 2016 Mar 1;213(5):738-45
PubMed ID: 26908781
PMC ID: PMC4747626
Groups or Programs: Chemopreventive Agent Development

Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

De Flora S,  Ganchev G,  Iltcheva M,  La Maestra S,  Micale RT,  Steele VE,  Balansky R
Trends Pharmacol Sci 2016 Feb;37(2):120-142
PubMed ID: 26726119
PMC ID: PMC4728041
Groups or Programs: Chemopreventive Agent Development

Introduction: Cancer chemoprevention and its context.

Dunn BK,  Umar A,  Richmond E
Semin Oncol 2016 Feb;43(1):19-21
PubMed ID: 26970121
PMC ID: PMC5166611
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM,  Gandini S,  Puntoni M,  Dunn BK,  DeCensi A,  Szabo E
Semin Oncol 2016 Feb;43(1):123-133
PubMed ID: 26970131
PMC ID: PMC4789107
Groups or Programs: Breast and Gynecologic CancerChemopreventive Agent DevelopmentLung and Upper Aerodigestive Cancer

Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.

López AM,  Pruthi S,  Boughey JC,  Perloff M,  Hsu CH,  Lang JE,  Ley M,  Frank D,  Taverna JA,  Chow HH
Cancer Prev Res (Phila) 2016 Feb;9(2):142-8
PubMed ID: 26667449
PMC ID: PMC4740217
Groups or Programs: Chemopreventive Agent Development

The promise of omics-based approaches to cancer prevention.

Meerzaman D,  Dunn BK,  Lee M,  Chen Q,  Yan C,  Ross S
Semin Oncol 2016 Feb;43(1):36-48
PubMed ID: 26970123
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentNutritional Science

The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Shoemaker RH,  Suen CS,  Holmes CA,  Fay JR,  Steele VE
Semin Oncol 2016 Feb;43(1):189-197
PubMed ID: 26970137
PMC ID: PMC4789768
Groups or Programs: Chemopreventive Agent DevelopmentProstate and Urologic Cancer

Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention.

Umar A,  Steele VE,  Menter DG,  Hawk ET
Semin Oncol 2016 Feb;43(1):65-77
PubMed ID: 26970125
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers

Hereditary cancer syndromes as model systems for chemopreventive agent development.

Walcott FL,  Patel J,  Lubet R,  Rodriguez L,  Calzone KA
Semin Oncol 2016 Feb;43(1):134-145
PubMed ID: 26970132
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other Cancers

Immunologic approaches to cancer prevention-current status, challenges, and future perspectives.

Wojtowicz ME,  Dunn BK,  Umar A
Semin Oncol 2016 Feb;43(1):161-172
PubMed ID: 26970135
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentGastrointestinal and Other CancersLung and Upper Aerodigestive Cancer

Validation of a Stability-Indicating Method for Methylseleno-L-Cysteine (L-SeMC).

Canady K,  Cobb J,  Deardorff P,  Larson J,  White JM,  Boring D
J Chromatogr Sci 2016 Jan;54(1):22-7
PubMed ID: 26199341
PMC ID: PMC4681365
Groups or Programs: Chemopreventive Agent Development

Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo.

Madka V,  Mohammed A,  Li Q,  Zhang Y,  Biddick L,  Patlolla JM,  Lightfoot S,  Towner RA,  Wu XR,  Steele VE,  Kopelovich L,  Rao CV
Cancer Prev Res (Phila) 2016 Jan;9(1):53-62
PubMed ID: 26577454
PMC ID: PMC4839263
Groups or Programs: Chemopreventive Agent Development

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

Dunn BK,  Steele VE,  Fagerstrom RM,  Topp CF,  Ransohoff D,  Cunningham C,  Lubet R,  Ford LG,  Kramer BS
J Natl Cancer Inst 2015 Dec;107(12):djv259
PubMed ID: 26420882
PMC ID: PMC4862414
Groups or Programs: BiometryChemopreventive Agent Development ;  Office of the Director

Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.

Joe AK,  Schnoll-Sussman F,  Bresalier RS,  Abrams JA,  Hibshoosh H,  Cheung K,  Friedman RA,  Yang CS,  Milne GL,  Liu DD,  Lee JJ,  Abdul K,  Bigg M,  Foreman J,  Su T,  Wang X,  Ahmed A,  Neugut AI,  Akpa E,  Lippman SM,  Perloff M,  Brown PH,  Lightdale CJ
Cancer Prev Res (Phila) 2015 Dec;8(12):1131-7
PubMed ID: 26471236
PMC ID: PMC4670789
Groups or Programs: Chemopreventive Agent Development

Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.

Kim MS,  Lim DY,  Kim JE,  Chen H,  Lubet RA,  Dong Z,  Bode AM
Mol Carcinog 2015 Dec;54(12):1596-604
PubMed ID: 25328014
PMC ID: PMC4402118
Groups or Programs: Chemopreventive Agent Development

Modulation by aspirin and naproxen of nucleotide alterations and tumors in the lung of mice exposed to environmental cigarette smoke since birth.

La Maestra S,  D'Agostini F,  Izzotti A,  Micale RT,  Mastracci L,  Camoirano A,  Balansky R,  Trosko JE,  Steele VE,  De Flora S
Carcinogenesis 2015 Dec;36(12):1531-8
PubMed ID: 26464196
PMC ID: PMC4675832
Groups or Programs: Chemopreventive Agent Development

Early and delayed intervention with rapamycin prevents NNK-induced lung adenocarcinoma in A/J mice.

Patlolla JM,  Kopelovich L,  Qian L,  Zhang Y,  Kumar G,  Madka V,  Mohammed A,  Biddick L,  Sadeghi M,  Lightfoot S,  Rao CV
Oncol Rep 2015 Dec;34(6):2925-34
PubMed ID: 26397133
PMC ID: PMC4735698
Groups or Programs: Chemopreventive Agent Development

Legislation in the genomic era: the Affordable Care Act and genetic testing for cancer risk assessment.

Walcott FL,  Dunn BK
Genet Med 2015 Dec;17(12):962-4
PubMed ID: 25741860
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.

Rao CV,  Janakiram NB,  Madka V,  Devarkonda V,  Brewer M,  Biddick L,  Lightfoot S,  Steele VE,  Mohammed A
Oncotarget 2015 Oct 20;6(32):33290-305
PubMed ID: 26429877
PMC ID: PMC4741766
Groups or Programs: Chemopreventive Agent Development

Metformin: risk-benefit profile with a focus on cancer.

Provinciali N,  Lazzeroni M,  Cazzaniga M,  Gorlero F,  Dunn BK,  DeCensi A
Expert Opin Drug Saf 2015 Oct;14(10):1573-85
PubMed ID: 26359221
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

Zhang S,  Zhou L,  Hong B,  van den Heuvel AP,  Prabhu VV,  Warfel NA,  Kline CL,  Dicker DT,  Kopelovich L,  El-Deiry WS
Cancer Res 2015 Sep 15;75(18):3842-52
PubMed ID: 26294215
PMC ID: PMC4573895
Groups or Programs: Chemopreventive Agent Development

Effect of ED-71, an analogue of Vitamin D3, on intestinal neoplasia in the Apc plus /Min-FCCC mouse model

Chang Wen-Chi L.,  Kaunga Esther,  Cooper Harry S.,  Vanderveer Lisa,  Peng Jing,  Zhang Yongchao,  Suen Chen S.,  Clapper Margie L.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2806
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Chemoprevention of mammary cancer: Modeling predictive values of short-term morphologic assays for efficacy in animal tumor assays

Dunn Barbara K.,  Steele Vernon E.,  Fagerstrom Richard M.,  Topp Carol F.,  Kramer Barnett S.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2813
PubMed ID: not available
PMC ID: not available
Groups or Programs: BiometryChemopreventive Agent Development ;  Office of the Director

Chemopreventive studies of multiple agents in the methylnitrosourea-induced ER+ mammary cancer model in animals on standard and Western diets

Grubbs Clinton J.,  Miller Mark S.,  Steele Vernon E.,  Moeinpour Fariba,  Seifried Harold,  Heckman-Stoddard Brandy M.,  Lubet Ronald A.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2809
PubMed ID: not available
PMC ID: not available
Groups or Programs: Breast and Gynecologic CancerChemopreventive Agent DevelopmentNutritional Science

Modulation of mTOR and p53 signaling using rapamycin plus CP-31398 inhibits growth and progression of urothelial carcinoma in-vivo

Madka Venkateshwar,  Mohammed Altaf,  Li Qian,  Zhang Yuting,  Biddick Laura,  Patlolla Jagan M. R.,  Lightfoot Stanley,  Wu Xue-Ru,  Steele Vernon,  Kopelovich Levy,  Rao Chinthalapally V.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 4653
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Targeting inflammation and pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression

Mohammed Altaf,  Janakiram Naveena B.,  Madka Venkateshwar,  Brewer Misty,  Ritchie Rebekah L.,  Lightfoot Stan,  Kumar Gaurav,  Sadeghi Michael,  Patlolla Jagan Mohan R.,  Yamada Hiroshi,  Cruz-Monserrate Zobeida,  Houchen Courtney W.,  Steele Vernon E.,  Rao Chinthalapally V.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2819
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Omeprazole alone, or in combination with Aspirin inhibits azoxymethane-induced colon adenoma progression to adenocarcinoma and carcinoma invasion in F344 rat model

Mohammed Altaf,  Patlolla Jagan M. R.,  Zhang Yuting,  Biddick Laura,  Madka Venkateshwar,  Li Qian,  Lightfoot Stan,  Lubel Ronald,  Suen Chen S.,  Steele Vernon E.,  Rao Chinthalapally V.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 2820
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent DevelopmentProstate and Urologic Cancer

Genomics-based resistome analysis revealed endogenous adenosine kinase levels as a chief determinant of specificity for a novel nucleoside analog lymphoma inhibitor

Nayar Utthara,  Reichel Jonathan,  Sadek Jouliana,  Hernandez-Hopkins Denise,  Akar Gunkut,  Zhou Hufeng,  Sahai Michelle A.,  Barelli Peter,  Guasparri Ilaria,  Totonchy Jennifer,  Hassane Duane,  Sei Shizuko,  Shoemaker Robert H.,  Warren J. David,  Elemento Olivier,  Kaye Kenneth M.,  Cesarman Ethel
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 4496
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Muscadine grape extract reduces lung carcinogenesis in female mice exposed to 3-methylcholanthrene in utero

Porter Brooke E.,  Moore Joseph E.,  Miller Mark S.,  Tallant E. Ann,  Gallagher Patricia E.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 4563
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Effects of dietary metformin/pioglitazone on lung adenoma formation in A/J mice

Seabloom Donna,  Galbraith Art,  Wuertz Beverly,  Haynes Anna,  Miller Mark S.,  Steele Vernon,  Wattenberg Lee,  Ondrey Frank G.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract LB-264
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Targeting STAT3 for mammary cancer prevention in MMTV/Neu mice employing the antagonist GLG-302

Shoemaker Robert H.,  Lovell Michael W.,  Whalen John J.,  Moeinpour Fariba,  Grubbs Clinton J.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 4657
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Correlation between modulation of RNA expression and the preventive and therapeutic efficacy of Tamoxifen in an ER plus model of breast cancer

Yang Howard H.,  Liu Huaitian,  Lubet Ronald,  Grubbs Clinton J.,  Nicastro Holly,  Lee Maxwell P.
Cancer Res 2015 Aug 1;75(Suppl 15):Abstract 896
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.

Mohammed A,  Janakiram NB,  Madka V,  Brewer M,  Ritchie RL,  Lightfoot S,  Kumar G,  Sadeghi M,  Patlolla JM,  Yamada HY,  Cruz-Monserrate Z,  May R,  Houchen CW,  Steele VE,  Rao CV
Oncotarget 2015 Jun 20;6(17):15524-39
PubMed ID: 25906749
PMC ID: PMC4558168
Groups or Programs: Chemopreventive Agent Development

A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'.

Glaze ER,  Roy MJ,  Dalrymple LW,  Lanning LL
Comp Med 2015 Jun;65(3):241-59
PubMed ID: 26141449
PMC ID: PMC4485633
Groups or Programs: Chemopreventive Agent Development

Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention.

Zhang Q,  Pan J,  Lubet RA,  Wang Y,  You M
Mol Carcinog 2015 Jun;54 Suppl 1:E129-37
PubMed ID: 25163779
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Vasomotor symptoms, BMI, and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1)

Walcott Farzana L.,  Land Stephanie R.,  Costantino Joseph P.,  Midthune Doug,  Dunn Barbara Karen
J Clin Oncol 2015 May 20;33(15):Abstract 1501
PubMed ID: not available
PMC ID: not available
Groups or Programs: BiometryChemopreventive Agent Development

Understanding predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal mammary gland tumor assays

Dunn Barbara K.,  Steele Vernon E.,  Topp Carol F.,  Fagerstrom Richard M.,  Kramer Barnett S.
Cancer Res 2015 May 1;75(9 Suppl):Abstract P5-06
PubMed ID: not available
PMC ID: not available
Groups or Programs: BiometryChemopreventive Agent Development ;  Office of the Director

Correlation of the effects of potential and known chemopreventive agents on proliferation rates in normal mammary glands and mammary cancers with their chemopreventive efficacy

Heckman-Stoddard Brandy M.,  Grubbs Clinton J.,  Moeinpour Fariba,  Steele Vernon E.,  Lubet Ronald A.
Cancer Res 2015 May 1;75(9 Suppl):Abstract P5-01
PubMed ID: not available
PMC ID: not available
Groups or Programs: Breast and Gynecologic CancerChemopreventive Agent Development

De-escalating doses of letrozole in post menopausal women at high risk for breast cancer

Lopez Ana Maria,  Chow Hsiao Hui Sherry,  Frank Denise,  Puthi Sandhya,  Boughey Judy,  Hsu Paul,  Guillen Jose,  Perloff Marjorie,  Ley Michelle,  Lang Julie E.
Cancer Res 2015 May 1;75(9 Suppl):Abstract P5-04
PubMed ID: not available
PMC ID: not available
Groups or Programs: Chemopreventive Agent Development

Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs.

Muzzio M,  Hu SC,  Holleran JL,  Parise RA,  Eiseman JL,  Yellow-Duke AE,  Covey JM,  Glaze ER,  Engelke K,  Egorin MJ,  McCormick DL,  Beumer JH
Cancer Chemother Pharmacol 2015 May;75(5):1015-23
PubMed ID: 25776905
PMC ID: PMC4420695
Groups or Programs: Chemopreventive Agent Development